| Literature DB >> 36166082 |
Dirk Stengel1, Wolf Mutschler2, Luzi Dubs3, Stephan Kirschner4, Tobias Renkawitz5.
Abstract
Clinical trials must be planned and interpreted in the context of current best clinical and scientific evidence, undoubtedly provided by systematic reviews and meta-analyses, especially Cochrane Reviews. While many clinicians feel overwhelmed by this complex data source, few visualElements (e.g., the traffic light system of the Cochrane risk of bias [RoB‑2] tool, forest plots, etc.), together with indices such as the I2 heterogeneity statistic, allow for a quick appraisal of all critical and necessary qualitative and quantitative information. The effectiveness of different treatment options can indirectly be assessed by methodological advancements like network meta-analyses.Point estimates of percentages are insufficient to describe the utility and value of a proposed novel intervention, which, in orthopedic and trauma surgery, often represents a step innovation. 95% confidence intervals and the so-called fragility index are helpful in determining the ultimate patient benefit.Entities:
Keywords: Clinical decision-making; Effect size; Evidence-based medicine; Network meta-analysis; Statistics
Year: 2022 PMID: 36166082 DOI: 10.1007/s00113-022-01244-2
Source DB: PubMed Journal: Unfallchirurgie (Heidelb) ISSN: 2731-7021